IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

RUMI, MARIAGRAZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 12.285
NA - Nord America 8.408
AS - Asia 7.931
SA - Sud America 769
AF - Africa 204
OC - Oceania 44
Continente sconosciuto - Info sul continente non disponibili 12
Totale 29.653
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.102
GB - Regno Unito 5.222
CN - Cina 2.524
SG - Singapore 2.287
DE - Germania 2.010
IT - Italia 1.232
SE - Svezia 915
RU - Federazione Russa 817
HK - Hong Kong 746
VN - Vietnam 717
BR - Brasile 524
IN - India 477
FR - Francia 414
UA - Ucraina 397
TR - Turchia 367
IE - Irlanda 295
NL - Olanda 293
KR - Corea 243
CA - Canada 225
FI - Finlandia 222
EU - Europa 187
DK - Danimarca 132
CO - Colombia 105
ID - Indonesia 104
BD - Bangladesh 79
JP - Giappone 76
CI - Costa d'Avorio 66
PL - Polonia 60
AR - Argentina 56
GR - Grecia 56
BE - Belgio 43
IQ - Iraq 40
PK - Pakistan 36
UZ - Uzbekistan 35
AU - Australia 34
MX - Messico 34
AT - Austria 33
IR - Iran 31
CH - Svizzera 30
ZA - Sudafrica 29
CL - Cile 27
EG - Egitto 27
RO - Romania 25
TW - Taiwan 25
ES - Italia 20
MA - Marocco 19
EC - Ecuador 17
PH - Filippine 16
MY - Malesia 15
KE - Kenya 14
SA - Arabia Saudita 14
CR - Costa Rica 13
IL - Israele 13
TH - Thailandia 13
VE - Venezuela 13
AE - Emirati Arabi Uniti 11
PE - Perù 11
AZ - Azerbaigian 9
JO - Giordania 9
PY - Paraguay 9
TN - Tunisia 9
UG - Uganda 9
PT - Portogallo 8
CZ - Repubblica Ceca 7
ET - Etiopia 7
NO - Norvegia 7
NP - Nepal 7
NZ - Nuova Zelanda 7
BY - Bielorussia 5
KZ - Kazakistan 5
BB - Barbados 4
CY - Cipro 4
DO - Repubblica Dominicana 4
EE - Estonia 4
GE - Georgia 4
GT - Guatemala 4
HU - Ungheria 4
JM - Giamaica 4
KG - Kirghizistan 4
MD - Moldavia 4
OM - Oman 4
PA - Panama 4
SC - Seychelles 4
SK - Slovacchia (Repubblica Slovacca) 4
IS - Islanda 3
KW - Kuwait 3
LT - Lituania 3
LV - Lettonia 3
LY - Libia 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BO - Bolivia 2
DZ - Algeria 2
GP - Guadalupe 2
KH - Cambogia 2
Totale 29.782
Salva come PNG Salva come JPEG
Città #
Southend 4.918
Singapore 1.280
Ashburn 823
Chandler 721
Hong Kong 678
Beijing 548
Frankfurt am Main 532
San Jose 484
Seattle 459
Milan 399
Princeton 330
Jacksonville 301
Dublin 290
Wilmington 284
Ann Arbor 229
Fairfield 217
Council Bluffs 214
Ho Chi Minh City 209
Los Angeles 209
Dallas 204
Dearborn 196
Bengaluru 184
Hanoi 172
Nanjing 172
New York 172
Santa Clara 172
Woodbridge 168
Hanover 161
Mountain View 159
Redmond 158
Toronto 158
Houston 147
Lauterbourg 145
Serra 131
Somerville 118
Andover 115
Des Moines 115
Boardman 111
Moscow 106
Shanghai 106
Buffalo 105
Sakarya 105
Bogotá 98
Hefei 94
Jinan 93
Guangzhou 90
Cambridge 89
Berlin 82
Helsinki 80
Munich 70
Shenyang 68
Phoenix 67
Abidjan 66
Nanchang 54
Tokyo 54
Columbus 53
Istanbul 53
Jakarta 52
Redwood City 50
The Dalles 48
Tianjin 48
São Paulo 46
Warsaw 46
Cangzhou 45
Jiaxing 43
Hebei 42
Saint Petersburg 42
Da Nang 41
Brussels 40
Dong Ket 40
Hangzhou 38
Athens 37
Changsha 34
Eitensheim 34
Turin 33
Grafing 31
Mumbai 30
Rome 30
Kunming 29
London 29
Zhengzhou 29
Haiphong 28
Ottawa 27
Shenzhen 27
Fremont 25
Fuzhou 25
Hamburg 25
Margão 25
San Diego 25
Segrate 25
Nuremberg 24
Bitonto 23
Auburn Hills 22
Pisa 22
Piscataway 22
Orem 21
Amsterdam 20
Atlanta 20
Taiyuan 19
Haikou 18
Totale 18.996
Salva come PNG Salva come JPEG
Nome #
Forecasting Hepatitis C liver disease burden on real life data: Does the hidden iceberg matter to reach the elimination goals? 679
Management of HCV-Related Liver Disease in Hemophilia and Thalassemia 402
Prevalence of psychiatric disorders during PEG – Interferon and Ribavirin therapy in patients with chronic hepatitis HCV-correlated 386
Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients 381
The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent 340
Anti-LAV/HTLV-III antibodies in groups of individuals at high risk for infection in Italy 321
Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance 320
High rates of 30-day mortality in patients with cirrhosis and COVID-19 305
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 292
A 28-Year Study of the Course of Hepatitis Delta Infection : A Risk Factor for Cirrhosis and Hepatocellular Carcinoma 285
The international autoimmune hepatitis group scoring system in patients with chronic hepatitis C and serum autoantibodies undergoing interferon/ribavirin therapy : a prospective validation study 272
Onset of inflammatory bowel disease during combined alpha-interferon and ribavirin therapy for chronic hepatitis C: report of two cases 266
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegykated interferon-α2A in chronic hepatitis C : an in vitro and in vivo study 264
Interleukin 28B genotype and insulin resistance in chronic hepatitis C patients 263
Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon 262
Anti-LAV/HTLV-III antibodies in high and low risk groups 258
Hepatitis C virus deletion mutants are found in individuals chronically infected with genotype 1 hepatitis c virus in association with age, high viral load and liver inflammatory activity 255
Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving telaprevir 246
Anemia during pegylated interferon-ribavirin therapy results from both increase suppression of erythroid differentiation and hemolysis 242
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 242
Anemia during peginterferon-ribavirin therapy results from both increased suppression of erythroid differentiation and haemolysis 240
Evaluation of three “beyond Baveno VI” criteria to safely spare endoscopies in compensated advanced chronic liver disease 240
Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C 239
Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma 239
US features of liver surface nodularity as a predictor of severe fibrosis in chronic hepatitis C 237
Outbreak of Acute Hepatitis A involving young men in Lombardy region, Italy: Risk factors, clinical and virological characteristics 237
Transmission of hepatitis G virus in patients with angioedema treated with steam-heated plasma concentrates of C1 inhibitor 235
Genotype dependent pattern of peginterferon alfa-2b/ribavirin treatment failure in hepatiti sC virus infected patients with cirrhosis : a single center study of 471 naive patients 231
Recovery after L-DOPA treatment in peg-interferon and ribavirin induced parkinsonism 230
The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy 228
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C 226
The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia 224
In vivo and in vitro effect of ribavirin and interferon on erythropoiesis in patients with hepatitis C 224
A sequential predictive algorithm combining APRI and transient elastography (TE) for diagnosing liver fibrosis in chronic hepatitis C 223
The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies 223
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 221
Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C 220
Serum hepatitis B virus DNA detects cryptic hepatitis B virus infections in multitransfused hemophilic patients 217
Minimal increases of serum alpha-foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy 215
Genotype dependent pattern of Peginterferon alfa-2B/Ribavirin treatment failure in hepatitis C virus infected patients with cirrhosis : a single centre study of 471 naïve patients 213
Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy 213
The candidate HCV E1E2MF59 vaccine is safe in chronic hepatitis C patients and accellerates the second phase viral decline upon primary response to peg-interferon-2A/ribavirin therapy 212
Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients 212
The natural history of portal hypertension in patients with HCV related compensated cirrhosis undergoing interferon ribavirin therapy 211
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegylated interferon-alpha 2a in chronic hepatitis C : an in vitro and in vivo study 210
Accelerated schedule of hepatitis B vaccination in patients with hemophilia 209
Predictors of psychopathological outcome during peg-interferon and ribavirin therapy in patients with chronic HCV-correlated hepatitis 209
Ribavirin impairs salivary gland function in hepatitis C patients during combination treatment with pegylated interferon alfa-2a 207
Natural history and clinical impact of cryoglobulins in chronic hepatitis C : 10-year prospective study of 343 patients 206
The influence of liver fibrosis on the outcome of pegylated interferon and ribavirin anti-hac therapy : a sub-analysis of the mist study 205
The diagnostic accuracy of fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with an SVR 205
The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype 204
Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4 204
Hepatitis C virus genotypes and patterns of peginterferon alfa-2b/ribavirin treatment failure in patients with cirrhosis : a single center study of 471 naïve patients 203
In vitro effect of ribavirin and pegylated interferon on erythropoiesis 202
Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection 202
Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs : high rates of sustained virologic response to pegylated interferon and ribavirin therapy 201
Primary prophylaxis of variceal bleeding in cirrhotic patients : a cohort study 201
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study 201
The candidate HCV E1E2MF59 vaccine enhances 2nd phase viral decline in responders to PEG-IFN/ribavirin 200
Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study 200
The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis 197
A morphometric and immunohistochemical study to assess the benefit of an svr in hcv cirrhotic patients 197
NPLA3 I148M polymorphism, steatosis, liver damage, and treatment response in chronic hepatitis C 196
Randomized Study of Peginterferon-alpha2a Plus Ribavirin vs Peginterferon-alpha2b Plus Ribavirin in Chronic Hepatitis C 196
Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients : a single-centre study 195
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting 194
Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c : a retrospective cohort study of 206 untreated patients 193
In vivo and in vitro effect of ribavirin and pegylated-interferon on erythropoiesis in patients with hepatitis C 192
Increased survival of patients with HCV-related cirrhosis with a long-term response to interferon therapy 192
PNPLA3 I148M polymorphism, steatosis, liver damage, and treatment response in chronic hepatitis C 192
Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection : a predictor of spontaneous viral clearance and sustained virological response 191
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 191
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis 189
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir 189
Outbreak of acute hepatitis A involving young men in Lombardy Region, Italy: risk factors, clinical and virological characteristics 187
Increased risk of hepatocellular carcinoma in HCV (+) non responder cirrhotics with high liver cell proliferation 186
A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort 185
Imatinib in CML patients HBCAB and/or HCVAB positive : report of two cases 185
Trattamento della cirrosi epatica HCV-correlata 184
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER cohort study (PLoS ONE (2017) 12: 2 (e0172159) DOI: 10.1371/journal.pone.0172159) 184
Accuracy of FIB-4 to Detect Elevated Liver Stiffness Measurements in Patients with Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study in Referral Centers 183
A multicenter controlled, randomized, open trial of interferon alpha2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C 183
Suboptimal response to hepatitis B vaccine in drug users 181
Interferoni pegilati nel trattamento dei pazienti con epatite cronica HCV : esperienze a confronti 180
Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B 180
Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3α hepatitis C virus infection 179
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegylated interferon-α2a in chronic hepatitis C: an in vitro and in vivo study 179
The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophilic males : an international, multicenter study 178
Antiviral Therapy for HCV-Associated Cryoglobulinemic Glomerulonephritis : Case Report and Review of the Literature 177
Low risk of hepatitis B reactivatioin in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 176
Standard and pegylated interferon alfa-2b plus ribavirin as initial treatment for HCV genotype 2 chronic hepatitis : analysis of a large single center cohort 175
Twelve-week post-treatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy 175
Optimizing treatment with pegylated interferon-ribavirin of genotype 3 chronic hepatitis C : more questions than answers 174
Low risk of hepatitis B reactivation in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 174
The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease : A cohort study 173
Evaluation of liver disease in a cohort of patients affected by thalassemia intermedia 173
Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1b chronic hepatitis C : A randomized controlled trial 170
Serum levels of hepatitis C virus core antigen as a markers of infection and response to therapy 170
In vivo and in vitro effect of ribavirin and interferon on erythropoiesis in patients with hepatitis C 169
Totale 22.324
Salva come PNG Salva come JPEG
Categoria #
all - tutte 83.938
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 83.938
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021842 0 0 0 0 0 0 0 0 0 0 592 250
2021/20222.280 230 115 69 127 139 161 225 192 238 277 157 350
2022/20232.426 323 269 204 281 260 482 46 125 270 23 106 37
2023/20241.790 45 115 77 142 529 118 129 107 59 93 153 223
2024/20253.578 155 414 63 412 270 114 103 342 207 322 336 840
2025/20267.209 844 437 810 569 710 530 1.169 443 729 572 396 0
Totale 31.068